The biotech company dosed its first patient in a phase 1 clinical trial Nov. 30 at MD Anderson to test NTX1088, a protein blocker targeting locally advanced and metastatic solid tumors.
“NTX1088’s triple mechanism of action represents a unique approach to treating challenging cancers, and we are excited by its potential to address a range of treatment-resistant tumors,” said Ross Barrett, a founder and managing partner of Cancer Focus Fund, in a Nov. 30 Nectin news release.
The funding round was led by Israel Biotech Fund and Peregrine Ventures. Cancer Focus Fund also partners with New Orleans-based Ochsner Health and LSU Health Shreveport (La.).
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
